Clinical Trials
8
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:1
Phase 3:5
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 3
5 (71.4%)Phase 1
1 (14.3%)Phase 4
1 (14.3%)Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
Phase 3
Completed
- Conditions
- CystitisUrinary Tract Infections
- Interventions
- Drug: Amoxicillin/clavulanate
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 2229
- Registration Number
- NCT05584657
- Locations
- 🇺🇸
Medical Facility, Morgantown, West Virginia, United States
🇺🇸Medical Facility3, Sugar Land, Texas, United States
🇺🇸Medical Facility2, Plano, Texas, United States
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
Phase 3
Withdrawn
- Conditions
- Respiratory Tract Infection Viral
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Registration Number
- NCT05026801
- Locations
- 🇺🇸
Waterbury Hospial, Waterbury, Connecticut, United States
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
Phase 1
Withdrawn
- Conditions
- Urinary Tract InfectionsPyelonephritis AcuteIntraabdominal Infections
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Registration Number
- NCT04700787
- Locations
- 🇺🇸
Medical Facility, Saint Louis, Missouri, United States
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Registration Number
- NCT04682834
Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)
Phase 4
Completed
- Conditions
- Antibiotic Resistant InfectionUTI - Lower Urinary Tract Infection
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Iterum Therapeutics, International Limited
- Target Recruit Count
- 250
- Registration Number
- NCT03366207
- Locations
- 🇺🇸
Restore Clinical Research, Cary, North Carolina, United States
- Prev
- 1
- 2
- Next
News
No news found